Online inquiry

IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15270MR)

This product GTTS-WQ15270MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets phosphatidylserine. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15270MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15467MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ3664MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ9858MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ5710MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ15831MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ4148MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ13919MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ11282MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW